Agios Pharmaceuticals, Inc. (AGIO) income statement
AGIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/308% above fair value
$29.68−0.21 (-0.70%)
Close on Nov 18, 2026Market cap $1.77BP/E –Yield –
Agios Pharmaceuticals, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 92.0%
- Operating margin
- -466.8%
- Net margin
- -418.2%
- Return on equity, FY2025
- -30.2%
Financial strength
- Current ratio
- 10.22
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 141.9%
Valuation
- P/E ratio
- –
- Price to sales
- 18.02
- Price to book
- 1.73
- Dividend yield
- –
See a number that looks wrong?